# A Study of ProQuad™ in Healthy Children in Korea (V221-023)

> **NCT00839917** · PHASE3 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 30 (actual)

## Conditions studied

- Measles
- Mumps
- Rubella
- Varicella

## Interventions

- **BIOLOGICAL:** Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (ProQuad™)
- **BIOLOGICAL:** M-M-R™ II and Varivax™

## Key facts

- **NCT ID:** NCT00839917
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-02
- **Primary completion:** 2008-05
- **Final completion:** 2008-05
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** Study terminated early because of insufficient enrollment before expiration date of the investigational vaccine lot
- **Last updated:** 2017-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00839917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00839917, "A Study of ProQuad™ in Healthy Children in Korea (V221-023)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00839917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*